A study investigating the safety, tolerability, absorption, excretion and effects of a new drug for the treatment of epilepsy.

You likely can't join if

• Evidence of any acute (at screening or prior to first dose) or chronic disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator (following a detailed medical history, physical examination, VSs [systolic and diastolic BP, PR, body temperature] and 12-lead ECG). Minor deviations from the normal range may be accepted, if judged by the Investigator to have no clinical relevance.
• History or presence of conditions which, in the judgment of the investigator, are known to interfere with the absorption, distribution, metabolism, or excretion of drugs
• History or presence of any condition that, in the judgment of the investigator, might increase the risk (or worsening) of infection, including but not limited to an active viral or bacterial infection, respiratory condition (e.g., asthma, chronic obstructive pulmonary disease, chronic sinusitis, or bronchitis), recent surgery or major trauma (within 12 weeks of screening), or surgery planned during the study period.
• History or presence of conditions which, in the judgment of the investigator, might increase the risk of performing TMS, including but not limited to epilepsy or febrile seizures, intracranial mass lesion, hydrocephalus, clinically significant head injury or trauma, metal objects in the brain or skull, cochlear implant or a deep brain stimulation device.
• Any condition that could interfere with the quality of or ability to perform TMS, such as an abnormal sleeping pattern (e.g., working night shifts), dreadlocks or hairpieces that cannot be removed or a rMT of more than 75% of the maximum stimulator output as measured using TMS-EMG during screening.